-
-
-
-
-
-
-
Jazz Pharmaceuticals adds former Global Blood Therapeutics CEO to board
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
-
-
-
-
-
-
-
Jazz Pharmaceuticals Completes Acquisition of Chimerix
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
-
-
-
-
-
-
-
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

